Twist Bioscience Q4 EPS $(0.81) Beats $(0.92) Estimate, Sales $66.95M Beat $63.45M Estimate
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience (NASDAQ:TWST) reported Q4 earnings with an EPS of $(0.81), surpassing the $(0.92) estimate, and sales of $66.95M, exceeding the $63.45M estimate. This reflects an EPS improvement of 10.99% and a sales increase of 16.82% compared to the same period last year.
November 17, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience reported better-than-expected Q4 results with an EPS beat of 11.96% and a sales beat of 5.50%, indicating improved financial performance.
Beating both EPS and sales estimates typically generates positive investor sentiment and can lead to a short-term increase in stock price. The reported growth over the previous year's performance further reinforces the positive outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100